Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23

Sumitomo Chemical to build new API and intermediates plant in Japan

The plant is scheduled to come on stream in September 2024

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers

Evonik sells Hanau pharma assets to ProChem in strategic portfolio shift

The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas

TDB supports Indigenous production of green pharma ingredients

Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients

Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz

The company highlighted continued demand strength and pricing resilience despite global disruptions

SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth

Revenue from operations climbed 13% to Rs. 886.87 crore

Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr

Transition to a fermentation-based globally integrated CDMO platform

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure